{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:40:52Z","timestamp":1783636852561,"version":"3.55.0"},"reference-count":12,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This was an open\u2010label, randomized, single\u2010dose, 2\u2010period, crossover clinical trial with an adaptive design to evaluate the bioequivalence and comparative pharmacokinetics of generic glecaprevir\/pibrentasvir versus the brand name product in healthy White male and female volunteers under fed conditions. Safety profiles were also assessed. A total of 56 healthy adult volunteers were enrolled and randomly assigned in a 1:1 ratio to receive a single dose of either the generic or reference formulation. After a 7\u2010day washout period, subjects received the alternate product. Blood samples were collected at pre\u2010specified time points up to 48\u00a0hours post\u2010dosing. Plasma concentrations of glecaprevir and pibrentasvir were determined using a validated high\u2010performance liquid chromatography\u2010tandem mass spectrometry method. The geometric mean ratios of the test to the reference formulation for maximum plasma concentration (C<jats:sub>max<\/jats:sub>) and area under the concentration\u2010time curve from drug administration to the last measurable concentration (AUC<jats:sub>0\u2010t<\/jats:sub>) fell within the predefined bioequivalence range of 80%\u2010125%. Both formulations demonstrated comparable pharmacokinetic profiles for glecaprevir and pibrentasvir, and can be considered bioequivalent. No adverse events were reported, and both formulations were well tolerated by all participants.<\/jats:p>","DOI":"10.1002\/cpdd.1463","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T08:48:35Z","timestamp":1723625315000},"page":"1331-1338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bioequivalence and Safety of Generic Glecaprevir\/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers"],"prefix":"10.1002","volume":"13","author":[{"given":"Sergei","family":"Noskov","sequence":"first","affiliation":[{"name":"City Hospital No. 3  Yaroslavl Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesya","family":"Parulya","sequence":"additional","affiliation":[{"name":"City Hospital No. 3  Yaroslavl Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Lutskova","sequence":"additional","affiliation":[{"name":"City Hospital No. 3  Yaroslavl Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arefeva","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Protsenko","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veniamin","family":"Banko","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniia","family":"Radaeva","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliia","family":"Matvienko","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gefen","sequence":"additional","affiliation":[{"name":"R&amp;D Center GEROPHARM  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Karnakova","sequence":"additional","affiliation":[{"name":"LLC \u201cCenter for Pharmaceutical Analytics\u201d  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Knyazeva","sequence":"additional","affiliation":[{"name":"LLC \u201cCenter for Pharmaceutical Analytics\u201d  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timofey","family":"Komarov","sequence":"additional","affiliation":[{"name":"LLC \u201cCenter for Pharmaceutical Analytics\u201d  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Archakova","sequence":"additional","affiliation":[{"name":"LLC \u201cCenter for Pharmaceutical Analytics\u201d  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Shohin","sequence":"additional","affiliation":[{"name":"LLC \u201cCenter for Pharmaceutical Analytics\u201d  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1041201"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/13814788.2022.2056161"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1444030"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00047"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.025"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20321"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.02.015"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.294"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00518.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T02:25:31Z","timestamp":1733106331000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/cpdd.1463"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1463","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"2024-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}